StockMarketWire.com - Clinical artificial intelligence company Sensyne Health said Bayer had become its preferred pharmaceutical partner to work together on the development of a national UK patient data capability.

Bayer joined Microsoft, EY, JP Morgan, and Peel Hunt in the consortium.

Under the terms of a new non-binding 'memorandum of understanding' Bayer would work with Sensyne Health and the consortium members as they develop proposals to scale Sensyne Health's current network of strategic research agreements with NHS Trusts.

The purpose of the network was to accelerate the discovery and development of new medicines and improve patient care through the analysis of large databases of anonymised patient data, using clinical artificial intelligence.

Bayer would provide Sensyne Health with strategic insight and advice regarding the research, development and commercialisation of new medicines, medical devices and biomarkers to aid the design of these proposals.




At 8:22am: [LON:SENS] Sensyne Health Plc Ord 10p share price was 0p at 178p



Story provided by StockMarketWire.com